Home Cell Cycle eIF

eIF

Other Cell Cycle Related Inhibitors

CDK ROCK Wee1 Aurora Kinase Chk PLK APC MPS1 Rho Myc
Cat.No. Product Name Information Product Use Citations Product Validations
S8994 Zotatifin (eFT226) Zotatifin (eFT226) is a highly effective and sequence-selective inhibitor of the RNA helicase eIF4A. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs, with an IC50 of 2 nM, and disrupts the assembly of the eIF4F initiation complex. By enhancing the interaction between eIF4A and polypurine RNA sequence or structural motifs, zotatifin converts eIF4A into a sequence-specific translation repressor, thereby regulating the translation of certain target genes. It also exhibits anti-tumor activity.
S0706 ISRIB ISRIB is an integrated stress response (ISR) inhibitor that potently reverses the effects of eukaryotic initiation factor 2α (eIF2α) phosphorylation.
EMBO J, 2025, 44(4):1107-1130
Cell Death Dis, 2025, 16(1):190
Cancer Cell Int, 2025, 25(1):245
S8275 Tomivosertib (eFT508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Nat Commun, 2025, 16(1):7853
Nat Commun, 2024, 15(1):9755
J Clin Invest, 2024, 134(16)e168393
S2923 Salubrinal Salubrinal is a selective inhibitor of eIF2α dephosphorylation and inhibits ER stress-mediated apoptosis with EC50 of ~15 μM in a cell-free assay.
J Virol, 2026, 100(5):e0210325
Cell Discov, 2025, 11(1):80
Cell Metab, 2025, 37(8):1715-1731.e11
Verified customer review of Salubrinal
S7369 4EGI-1 4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.
Nat Commun, 2024, 15(1):4083
Nucleic Acids Res, 2024, gkae849
J Biol Chem, 2024, 300(11):107866
Verified customer review of 4EGI-1
S7370 4E1RCat 4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E.
Cancer Research Communications, 2024, 2454-2462
Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Verified customer review of 4E1RCat
S8181 SBI-0640756 SBI-0640756(SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-κB signaling.
Cell Reports Medicine, 2024, 101731
Neoplasia, 2024, 101109
Neoplasia, 2024, 60:101109
E6814New APL-4098 APL-4098 is an orally active, selective, ATP‑competitive GCN2 (EIF2AK4) inhibitor with Ki of 4.39 nM and Kd of 2.9 nM. APL‑4098 impairs mitochondrial function and triggers the mitochondrial unfolded protein response, leading to cytotoxicity in primary AML cells, including leukemia stem cells.
S6533 Briciclib Briciclib (ON-014185) is a water soluble derivative of ON-013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E).
S9668 PKR-IN-C16 PKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). This compound prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
Blood, October 20, 2025, 557-572
Respiratory Research, May 9, 2024, 201
Respiratory Research, 9 May 2024, 25(1):201